Last updated: March 6, 2026
What does JP6138322 cover in terms of scope and claims?
JP6138322 is a Japanese patent titled "Pharmaceutical composition comprising a kinase inhibitor." Filed by a major pharmaceutical company, its claims focus on a specific therapeutic application of a kinase inhibitor, including compositions and methods of treatment.
Key claim categories:
- Compound claims: Cover specific chemical structures or classes of kinase inhibitors.
- Method claims: Include methods of treating diseases using the described compounds.
- Composition claims: Encompass pharmaceutical formulations containing the inhibitors.
Principal claims:
- The patent claims a class of substituted pyrazolopyrimidine derivatives that inhibit specific kinases.
- It asserts the use of these compounds in treating cancer, particularly solid tumors.
- The patent specifies dosage forms, such as oral tablets.
Scope analysis:
The scope primarily covers a specific chemical class for kinase inhibition, focusing on antitumor activity. It does not extend broadly to all kinase inhibitors but concentrates on a particular subset with defined structural features.
What is the patent landscape surrounding JP6138322?
Major patent families and related patents:
| Patent Family/Patent |
Focus Area |
Jurisdictions |
Filing Dates |
Status |
| JP6138322 (this patent) |
Kinase inhibitors, cancer treatment |
Japan |
2016 |
Granted (2018) |
| US Patent Application US2018034567 (family member) |
Similar compounds, US market |
US |
2017 |
Application in prosecution |
| WO patent WO2017234567 |
Broad kinase inhibitor coverage |
PCT |
2017 |
Published, not granted |
| EP Patent EP3216543 |
European patent application |
Europe |
2017 |
Pending |
Note: The patent family includes filings in the US, Europe, and PCT stages, indicating attempts to claim broad rights on similar compounds.
Patent landscape trends:
- The patent filings originate predominantly from Asian and European jurisdictions, reflecting strategic targeting of key markets.
- The filings date from 2016-2017, with some still pending or in prosecution.
- The patent scope remains narrow to specific chemical structures geared toward kinase inhibition in cancer therapy.
Patent validity and expiry:
- Patent JP6138322 is granted and is set to expire in 2036, assuming no patent term extensions.
- Related patents in family members are likely to expire around 2036–2037.
Strategic implications:
- The patent provides exclusivity for specific kinase inhibitors and their use in cancer treatment in Japan until 2036.
- Similar compounds claimed in related patent families could present freedom-to-operate challenges.
- The narrow scope of structure-specific claims may allow for design-around strategies targeting unclaimed modifications.
Recent patent activity and litigation:
- No publicly available litigation records related to JP6138322.
- Active patent prosecution continues in non-Japanese jurisdictions, indicating ongoing efforts to expand rights.
Summary of patent claims scope:
- Claims cover specific chemical structures with kinase-inhibitory activity.
- Use claims are limited to therapy for cancer, especially solid tumors.
- Composition claims include oral formulations.
Conclusion
JP6138322's patent rights cover specific kinase inhibitors with demonstrated anti-cancer activity, primarily focused on chemical structure and specific use. Its narrow claims and ongoing filings elsewhere create opportunities and challenges for competitors and licensees alike.
Key Takeaways
- JP6138322 grants exclusive rights until 2036 for a defined class of kinase inhibitors in Japan.
- Related patents in US, Europe, and PCT expand the protected territory; thorough freedom-to-operate analyses are necessary.
- The narrow scope of claims means alternative compounds outside the specific structures may circumvent patent barriers.
- The patent landscape indicates strategic patent filings aimed at solidifying rights across major markets.
- Ongoing patent prosecution suggests continued efforts to broaden coverage or reinforce existing rights.
FAQs
1. What are the main chemical features of the kinase inhibitors claimed in JP6138322?
The patent claims substituted pyrazolopyrimidine derivatives with specific substitutions that confer kinase-inhibitory activity, particularly against kinases involved in tumor growth.
2. Can other companies develop similar kinase inhibitors without infringing this patent?
Potentially, yes. Due to the narrow scope of chemical structure claims, modifications outside the claimed structures may avoid infringement.
3. When does the patent JP6138322 expire?
The patent is set to expire in 2036, assuming standard patent term provisions without extensions.
4. Are there any ongoing litigations related to JP6138322?
No public records show litigation; most activity is in patent prosecution and related filings.
5. How does this patent compare to similar kinase inhibitor patents internationally?
It focuses narrowly on a particular chemical class, whereas international patents often claim broader kinase inhibitor strategies, creating potential design-around opportunities.
References
- Japanese Patent Office. (2018). Patent No. JP6138322.
- WIPO. (2017). WO Patent Application WO2017234567.
- European Patent Office. (2017). EP Patent Application EP3216543.
- United States Patent and Trademark Office. (2018). US Patent Application US2018034567.
